<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308553</url>
  </required_header>
  <id_info>
    <org_study_id>Nipawilma_2013</org_study_id>
    <nct_id>NCT02308553</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma</brief_title>
  <acronym>NIPAWILMA</acronym>
  <official_title>Phase I/II,Multicenter,Randomized,Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Dirk Schadendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alcedis GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled phase I/II trial designed
      to characterize the safety and estimate the efficacy of nintedanib when combined with
      paclitaxel chemotherapy compared with paclitaxel chemotherapy alone in patients with BRAF
      wild type metastatic melanoma not previously treated with taxanes or kinase inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Phase I: Run-In-Phase Based on acceptable safety data for nintedanib monotherapy, a
      rapid dose finding will be conducted in a classical 3+3 design. Predefined dose levels are
      150 mg (dose level 1) and 200 mg (dose level 2) nintedanib, twice daily, with weekly
      paclitaxel 90 mg/m2.

      Study Phase II Patients with advanced (unresectable Stage III or IV) BRaf V600 wild type
      melanoma (n=120) will be randomized (1:1) to receive either Nintedanib (150 or 200 mg BID
      depending on results of phase I) in combination with paclitaxel or Placebo in combination
      with paclitaxel.

      Total study duration per patient: approximately 12 months of therapy + Follow up until end of
      study

      All patients enrolled in either phase I or phase II will be treated according to the
      following treatment plan:

      Week 1 - 24:

      Chemotherapy with paclitaxel combined with nintedanib/placebo

      Week 25 - 48:

      Extended monotherapy with nintedanib/placebo

      Week 52 (or approximately 4 weeks after last treatment dose):

      End of Treatment visit

      Follow up:

      After end of treatment the survival, disease status and further therapies of each patient
      will be assessed every 3 months until death, progression of disease or end of study whichever
      occurs first
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>12 months after LPI</time_frame>
    <description>Time from administration of first study drug to the date of first documented progression or death due to any cause, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months after LPI</time_frame>
    <description>Time from the date of first administration of study drug to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity (graded according to CTCAE, Version 4.0)</measure>
    <time_frame>12 months after LPI</time_frame>
    <description>Reporting of adverse events from the date of first administration of study drug until 30 days after last administration of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EORTC QLQ-C30)</measure>
    <time_frame>12 months after LPI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Cutaneous Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Nintedanib + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nintedanib-Placebo + Paclitaxel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Nintedanib (150 mg or 200 mg BID)</description>
    <arm_group_label>Nintedanib + Paclitaxel</arm_group_label>
    <other_name>Vargatef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib-Placebo</intervention_name>
    <description>Placebo (150 mg or 200 mg BID)</description>
    <arm_group_label>Nintedanib-Placebo + Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)</description>
    <arm_group_label>Nintedanib + Paclitaxel</arm_group_label>
    <arm_group_label>Nintedanib-Placebo + Paclitaxel</arm_group_label>
    <other_name>Taxomedac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed, (surgically incurable or unresectable) stage III or IV, BRAF
             V600 wildtype metastatic cutaneous malignant melanoma.

          2. Written informed consent

          3. A minimum of 1 measurable lesion according to RECIST v1.1 criteria.

          4. ECOG of 0-1.

          5. Adequate hematologic, renal and liver function within 14 days prior to initiation of
             dosing:

               -  Hematologic:

                    -  Absolute neutrophil count (ANC) ≥1.5 x 109/L

                    -  Hemoglobin ≥ 9 g/dL (5.6 mmol/L; Subjects may not have had a transfusion
                       within 7 days of screening assessment)

                    -  Platelets: ≥ 100 x 109/L

               -  Hepatic

                    -  Total bilirubin: ≤ 1.0 x ULN

                    -  AST and ALT: ≤ 1.5 x ULN (In the case of liver metastases: 2.5 x ULN)

               -  Renal o Serum creatinine: ≤ 1.5 mg/dL (133 µmol/L) or, if greater than 1.5 mg/dL:
                  Calculated creatinine clearance: ≥ 50 mL/min

          6. effective method of contraception for at least 3 months after completion of
             nintedanib/placebo monotherapy as directed by their physician.

          7. Men should use an effective method of contraception during treatment and for at least
             6 months after completion of paclitaxel treatment and for at least 3 months after
             completion of nintedanib/placebo monotherapy as directed by their physician.

          8. Patients must have recovered from all prior treatment-related toxicities to NCI CTCAE
             (v4.0) Grade of 0 or 1, except for toxicities not considered a safety risk such as
             alopecia.

          9. Male or female, aged 18 years or older

         10. Life expectancy at least 3 months

        Exclusion Criteria:

          1. Prior systemic therapy with taxanes or kinase inhibitors. Any prior therapy for
             metastatic disease must have been discontinued at least 4 weeks prior to initiation of
             dosing.

          2. Major surgery or radiation therapy within 4 weeks of starting the study treatment
             (minor surgical procedures such as biopsies are allowed, however patients must have
             recovered).

          3. Known inherited predisposition to bleeding or thrombosis and therapeutic
             anticoagulation (except low-dose heparin and/or heparin flush as needed for
             maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for
             low-dose therapy with acetylsalicylic acid &lt; 325mg per day)

             Patients with the following coagulation parameters will be excluded:

               -  International normalised ratio (INR) &gt; 2

               -  Prothrombin time (PT) and partial thromboplastin time (PTT): &gt; 50% of deviation
                  of institutional ULN

          4. History of clinically significant haemorrhagic or thromboembolic event in the past 6
             months

          5. NCI CTCAE (V4.0) grade 3 hemorrhage within 4 weeks of starting the study treatment.

          6. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to randomization.

          7. Serious, non-healing wound, ulcer, or bone fracture.

          8. Known CNS disease:

               -  Previous Grade 2 or higher sensory neuropathy.

               -  History of or known spinal cord compression, or carcinomatous meningitis, or
                  evidence of active brain metastases (e.g. stable for &lt;4 weeks, no adequate
                  previous treatment with radiotherapy, symptomatic, requiring treatment with
                  anti-convulsants; dexamethasone therapy will be allowed if administered as stable
                  dose for at least one month before randomization) or leptomeningeal disease on
                  screening CT or MRI scan.

          9. Any of the following within the 6 months prior to enrolment: myocardial infarction,
             severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic
             congestive heart failure, cerebrovascular accident or transient ischemic attack, or
             pulmonary embolism.

         10. New York Heart Association (NYHA) Grade II or greater congestive heart failure.

         11. Ongoing cardiac dysrhythmias of NCI CTCAE Version 4.0 grade ≥ 2.

         12. Inadequately controlled hypertension (defined as systolic blood pressure &gt; 150 and/or
             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications).

         13. Symptomatic peripheral vascular disease.

         14. Proteinuria at screening as demonstrated by urine dipstick for proteinuria ≥ 2+
             (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline
             should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24
             hours to be eligible).

         15. Known hypersensitivity reaction to any of the components of study treatment (e.g.
             contrast media) or other severe acute or chronic medical or psychiatric condition or
             laboratory abnormality that may increase the risk associated with study participation
             or study drug administration, or may interfere with the interpretation of study
             results, and in the judgment of the investigator would make the subject inappropriate
             for entry into this study.

         16. Previous cancer (unless a RFS interval of at least 5 years) with the exception of
             surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma
             of the skin.

         17. Known clinically uncontrolled infectious disease including HIV positivity or
             AIDS-related illness and active or chronic hepatitis C and/or B infection.

         18. Pregnancy (absence to be confirmed by ß-hCG test) or lactation period.

         19. Psychological, familial, sociological or geographical factors potentially hampering
             compliance with the study protocol and follow-up schedule

         20. Active alcohol or drug abuse

         21. Treatment with other investigational drugs or treatments in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial.

         22. Legal incapacity or limited legal capacity

         23. Significant weight loss (&gt; 10% of body weight) within past 6 months prior to inclusion
             into the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Schadendorf, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk Schadendorf, Prof. Dr.</last_name>
    <phone>+49 201-723</phone>
    <phone_ext>4342</phone_ext>
    <email>Dirk.Schadendorf@uk-essen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Schadendorf, Prof. Dr.</last_name>
      <phone>+49-201- 723</phone>
      <phone_ext>4342</phone_ext>
      <email>dirk.schadendorf@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Dirk Schadendorf, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elbeklinikum Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Mohr, Dr. med.</last_name>
      <email>peter.mohr@elbekliniken.de</email>
    </contact>
    <investigator>
      <last_name>Peter Mohr, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Kaatz, PD Dr.</last_name>
      <email>martin.kaatz@wkg.srh.de</email>
    </contact>
    <investigator>
      <last_name>Martin Kaatz, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Centre for Tumour Diseases (NCT)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Hassel, Dr. med.</last_name>
      <email>jessica.hassel@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Jessica Hassel, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Pföhler, PD Dr.</last_name>
      <email>claudia.pfoehler@uks.eu</email>
    </contact>
    <investigator>
      <last_name>Claudia Pföhler, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Dippel, Prof. Dr.</last_name>
      <email>dippele@klilu.de</email>
    </contact>
    <investigator>
      <last_name>Edgar Dippel, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Terheyden, PD Dr.</last_name>
      <email>patrick.terheyden@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Patrick Terheyden, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital München</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carola Berking, Prof. Dr.</last_name>
      <email>carola.berking@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Carola Berking, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fachklinik Hornheide</name>
      <address>
        <city>Münster</city>
        <zip>48157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fluck, Dr. med.</last_name>
      <email>michael.fluck@fachklinik-hornheide.de</email>
    </contact>
    <investigator>
      <last_name>Michael Fluck, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Dirk Schadendorf</investigator_full_name>
    <investigator_title>Prof. Dr. med. Dirk Schadendorf</investigator_title>
  </responsible_party>
  <keyword>BRAF V600 wildtype</keyword>
  <keyword>cutaneous malignant melanoma</keyword>
  <keyword>nintedanib</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

